ABVC Biopharma In…
USUSDABVC Biopharma Inc (US:ABVC) — Biotechnology: Pharmaceutical Preparations. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 2. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie įmonę
- Svetainė
- abvcpharma.com
- Sektorius
- Health Care · Biotechnology: Pharmaceutical Preparations
- Būstinė
- FREMONT, United States
- Generalinis direktorius
- Dr. Uttam Yashwant Patil Ph.D.
- Darbuotojai
- 16
- Apyvartoje esančios akcijos
- 26.65 mln. 2026-08-10 duomenimis
- Laisvai apyvartinės akcijos
- 21.1 mln.
- Rinkos kapitalizacija
- 27.99 mln. USD
- Insaideriai
- 18.11%
- Instituciniai investuotojai
- 4.09%
- Šaka (SIC)
- Pharmaceutical Preparations
Aprašymas
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Dividendai
Dividendų išmokų nerasta (patikrinta 06.10.2026). Įmonė greičiausiai nemoka dividendų.
News this week
Naujienų iš įmonės svetainės kol kas nėra.
Didžiausi akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos data |
|---|---|---|---|
| Vanguard Capital Managem… | 1.41% | 374 499 | 2026-06-30 |
| Geode Capital Management… | 0.86% | 228 042 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.78% | 208 279 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.43% | 115 243 | 2026-06-30 |
| Fidelity Concord Street… | 0.41% | 109 472 | 2026-07-31 |
| Vanguard Fiduciary Trust… | 0.37% | 97 363 | 2026-06-30 |
| State Street Corporation | 0.27% | 72 800 | 2026-06-30 |
| Citadel Advisors Llc | 0.27% | 72 091 | 2026-06-30 |
| Blackrock Inc. | 0.21% | 56 442 | 2026-06-30 |
| Northern Trust Corporati… | 0.18% | 48 643 | 2026-06-30 |
| Xtx Topco Ltd | 0.18% | 48 276 | 2026-06-30 |
| PanAgora Asset Managemen… | 0.14% | 36 682 | 2026-06-30 |
| Fidelity Concord Street… | 0.13% | 35 530 | 2026-07-31 |
| UBS Group AG | 0.13% | 34 123 | 2026-06-30 |
| Fidelity Concord Street… | 0.12% | 31 053 | 2026-07-31 |
| Fidelity Concord Street… | 0.06% | 14 820 | 2026-07-31 |
